Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 Vaccines market in Hungary has been experiencing steady growth since the introduction of vaccines in the country.
Customer preferences: Hungary has a population of approximately 9.8 million people, with a majority of the population being vaccinated against COVID-19. The demand for vaccines has been high, with people willing to take the vaccine as soon as it is available to them. The government has made it easy for people to access the vaccine by setting up vaccination centers in different parts of the country.
Trends in the market: The COVID-19 Vaccines market in Hungary has been growing steadily since the introduction of vaccines in the country. The demand for vaccines has been high, with people willing to pay for the vaccine if it is not available for free. The government has been working to ensure that the vaccine is available to everyone, regardless of their financial status. The COVID-19 Vaccines market in Hungary is expected to continue growing as more people get vaccinated.
Local special circumstances: Hungary has been working to increase its vaccination rate to reach herd immunity. The government has been promoting the vaccine and encouraging people to get vaccinated. The government has also been working to ensure that the vaccine is available to everyone, regardless of their financial status. Hungary has also been working to increase its vaccine production capacity to meet the high demand for vaccines.
Underlying macroeconomic factors: The COVID-19 Vaccines market in Hungary has been influenced by various macroeconomic factors. The government's efforts to increase vaccination rates have had a positive impact on the market. The government's investment in vaccine production has also contributed to the growth of the market. The country's strong healthcare system has also played a role in the success of the vaccine rollout. Additionally, Hungary's location in the heart of Europe has made it a strategic location for vaccine distribution to other countries in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
